Unite the Power of Nanotechnology and Immunity for the Fight to Cancer and COVID-19
By developing novel combination immunotherapies utilizing our potent anti-tumor T cell activating nano-immunotherapy “T-ignite”, we challenge conquest of intractable solid cancer, especially “cold tumor”, where conventional therapies are not effective for. The same technology is being used for the development of a next generation SARS-CoV-2 nanoparticle vaccine.
|January 14, 2021||United Immunity and Xyphos, an Astellas company, entered into a joint research agreement to discover next gen nano-immunotherapies.|
|January 4, 2021||Japan AMED decided to provide the company an R&D grant ($3M) for our new program to develop a new T-ignite product for the treatment of advanced solid cancers.|
|October 26, 2020||A joint team of United Immunity, Kyoto University, and Nagasaki University published an article reporting a new animal model for the evaluation of immunogenicity of SARS-CoV-2 vaccines.|
|July 31, 2020||Japan AMED decided to provide the company an R&D grant ($3M) for our new program to develop a next gen SARS-CoV-2 nanoparticle vaccine.|
|June 7, 2019||United Immunity, Co. Ltd. increased its capital through third-party allocation of new shares from Mitsubishi UFJ Capital, Co., Ltd. and Axil Capital Partners LLP to accelerate its research and development activity.|
|January 11, 2019||A research article describing the treatment of immune-resistant cold tumors using T-ignite technology was recently published online on the Journal of Clinical Investigation.
Article: Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Daisuke Muraoka, … , Naozumi Harada, Hiroshi Shiku, et al. J Clin Invest. 2019. https://doi.org/10.1172/JCI97642.
|July 2, 2018||An investigator-initiated phase 1/2 study on a combination of T-ignite and gene-engineered T cells for the treatment of soft tissue sarcomas has begun in Japan.|
(Next page “Our Science and Technology”)